HRP980370B1 - Polymorphic form of a tachykinin receptor antagonist - Google Patents

Polymorphic form of a tachykinin receptor antagonist

Info

Publication number
HRP980370B1
HRP980370B1 HR980370A HRP980370A HRP980370B1 HR P980370 B1 HRP980370 B1 HR P980370B1 HR 980370 A HR980370 A HR 980370A HR P980370 A HRP980370 A HR P980370A HR P980370 B1 HRP980370 B1 HR P980370B1
Authority
HR
Croatia
Prior art keywords
phenyl
polymorphic form
receptor antagonist
tachykinin receptor
triazolo
Prior art date
Application number
HR980370A
Other languages
English (en)
Inventor
Louis Crocker
James Mccauley
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800216.5A external-priority patent/GB9800216D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HRP980370A2 publication Critical patent/HRP980370A2/hr
Publication of HRP980370B1 publication Critical patent/HRP980370B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyamides (AREA)
  • Polyurethanes Or Polyureas (AREA)
HR980370A 1997-07-02 1998-07-01 Polymorphic form of a tachykinin receptor antagonist HRP980370B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5160097P 1997-07-02 1997-07-02
GBGB9800216.5A GB9800216D0 (en) 1998-01-07 1998-01-07 Polymorphic form of a tachykinin receptor antagonist

Publications (2)

Publication Number Publication Date
HRP980370A2 HRP980370A2 (en) 1999-04-30
HRP980370B1 true HRP980370B1 (en) 2002-10-31

Family

ID=26312895

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980370A HRP980370B1 (en) 1997-07-02 1998-07-01 Polymorphic form of a tachykinin receptor antagonist

Country Status (27)

Country Link
EP (1) EP0994867B1 (cs)
JP (1) JP2000513383A (cs)
KR (1) KR20010020593A (cs)
CN (1) CN1106390C (cs)
AT (1) ATE372991T1 (cs)
AU (1) AU735230B2 (cs)
BG (1) BG64703B1 (cs)
CA (1) CA2293836C (cs)
CZ (1) CZ295410B6 (cs)
DE (1) DE69838421D1 (cs)
DZ (1) DZ2551A1 (cs)
EA (1) EA002405B1 (cs)
EE (1) EE04152B1 (cs)
HK (1) HK1029345A1 (cs)
HR (1) HRP980370B1 (cs)
HU (1) HU228003B1 (cs)
ID (1) ID23191A (cs)
IL (1) IL133357A (cs)
IS (1) IS2617B (cs)
NO (1) NO316893B1 (cs)
NZ (1) NZ501589A (cs)
PE (1) PE86499A1 (cs)
PL (1) PL191496B1 (cs)
SK (1) SK285644B6 (cs)
TR (1) TR199903299T2 (cs)
TW (1) TW577887B (cs)
WO (1) WO1999001444A1 (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1343901A (en) 1999-10-29 2001-05-14 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
ES2299720T3 (es) * 2002-05-31 2008-06-01 Schering Corporation Formas polimorfas de un inhibidor de xantina-fosfodiesterasa v.
GB0417702D0 (en) * 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
EP2266980A1 (en) 2005-10-05 2010-12-29 Ranbaxy Laboratories Limited Polymorphic form of aprepitant intermediate
US9227958B2 (en) 2006-02-03 2016-01-05 Glenmark Pharmaceuticals Limited Amorphous and crystalline forms of aprepitant and processes for the preparation thereof
SG10201500027TA (en) * 2006-04-05 2015-02-27 Opko Health Inc Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
WO2008026216A2 (en) * 2006-08-28 2008-03-06 Hetero Drugs Limited Process for purification of aprepitant
WO2008044102A1 (en) * 2006-10-13 2008-04-17 Glenmark Pharmaceuticals Limited Polymorph form of aprepitant and process for the preparation thereof
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
HUE036546T2 (hu) * 2008-02-18 2018-07-30 Esteve Labor Dr Szigma-receptor ligandumokhoz kötõdõ vegyületek alkalmazása kemoterápia következményeként kifejlõdõ neuropátiás fájdalom kezelésére
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
JP5998933B2 (ja) * 2011-06-30 2016-09-28 東レ株式会社 グリシン誘導体の結晶及びその医薬用途
CN103030668B (zh) * 2011-10-09 2016-06-15 江苏豪森药业集团有限公司 一种制备福沙匹坦二甲葡胺的方法
CZ304770B6 (cs) 2012-03-13 2014-10-08 Zentiva, K.S. Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II
CN102850339B (zh) * 2012-10-17 2014-10-15 上海博志研新药物技术有限公司 一种神经激肽(nk-1)受体拮抗剂晶型制备方法
CN103288813A (zh) * 2013-06-04 2013-09-11 四川百利药业有限责任公司 一种阿瑞匹坦的制备方法
WO2015091508A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
CN104119325B (zh) * 2014-07-15 2017-03-22 中山奕安泰医药科技有限公司 阿瑞吡坦多晶型物的制备方法
CN105837526B (zh) * 2016-01-22 2018-02-27 浙江工业大学 一种阿瑞吡坦重要合成中间体(2s,3r)‑4‑苄基‑3‑(4‑氟苯基)吗啉‑2‑醇的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EE9900603A (et) 2000-08-15
NZ501589A (en) 2001-10-26
AU8283398A (en) 1999-01-25
IS2617B (is) 2010-04-15
CA2293836A1 (en) 1999-01-14
TR199903299T2 (xx) 2000-07-21
EP0994867A1 (en) 2000-04-26
EP0994867B1 (en) 2007-09-12
ID23191A (id) 2000-03-23
BG64703B1 (bg) 2005-12-30
TW577887B (en) 2004-03-01
CN1261882A (zh) 2000-08-02
NO996549D0 (no) 1999-12-29
ATE372991T1 (de) 2007-09-15
HK1029345A1 (en) 2001-03-30
HU228003B1 (en) 2012-08-28
CZ477799A3 (cs) 2000-09-13
AU735230B2 (en) 2001-07-05
CN1106390C (zh) 2003-04-23
KR20010020593A (ko) 2001-03-15
CA2293836C (en) 2007-06-05
PL337579A1 (en) 2000-08-28
CZ295410B6 (cs) 2005-08-17
JP2000513383A (ja) 2000-10-10
NO996549L (no) 2000-03-01
SK285644B6 (sk) 2007-05-03
DE69838421D1 (en) 2007-10-25
IL133357A (en) 2003-12-10
IS5293A (is) 1999-12-10
WO1999001444A1 (en) 1999-01-14
HRP980370A2 (en) 1999-04-30
HUP0004008A2 (hu) 2002-02-28
EE04152B1 (et) 2003-10-15
IL133357A0 (en) 2001-04-30
EA199901114A1 (ru) 2000-08-28
EA002405B1 (ru) 2002-04-25
NO316893B1 (no) 2004-06-14
DZ2551A1 (fr) 2003-08-15
PE86499A1 (es) 1999-10-25
SK187299A3 (en) 2000-07-11
HUP0004008A3 (en) 2002-03-28
PL191496B1 (pl) 2006-05-31
BG104010A (en) 2001-08-31

Similar Documents

Publication Publication Date Title
ZA985765B (en) Polymorphic form of a tachykinin receptor antagonist.
HRP980370B1 (en) Polymorphic form of a tachykinin receptor antagonist
MY155911A (en) Pharmaceutical composition of a tachykinin receptor antagonist
AU3401797A (en) Compounds having effects on serotonin-related systems
IL114474A (en) (R)-(3)-3-(1H-indol-3-yl)-1-[N-(2-methoxybenzyl)acetylamino]-2-[N-(2-(4-piperidin-1-yl)piperidin-1-yl acetyl)amino]propane dihydrochloride trihydrate and tachykinin receptor antagonistic pharmaceutical compositions containing it
ZA955867B (en) Triazol compounds and their use
MY126509A (en) Polymorphic form of a tachykinin receptor antagonist
WO2002034699A3 (en) Mammalian metabolites of a tachykinin receptor antagonist
AR026288A1 (es) Forma polimorfica de un antagonista del receptor de taquicinina
AU2001269749A1 (en) Trans-glycosidation process for the synthesis of (2r, 2-alpha-r, 3a)-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-3-(4-fluorophenyl)-1,4-oxazine
WO2002024727A3 (en) New inhibitors of iapp fibril formation and uses thereof
CA2262267A1 (en) Anti-migraine pharmaceutical compositions and process of using
ECSP982575A (es) Forma polimorfica de un antagonista de receptor de taquiquinina
ECSP003740A (es) Forma polimorfica de un antagonista de receptor de taquiquinina
BR9810360A (pt) Forma polimórfica do composto 2-(r)-(1-(r) - (3,5-bis(tri-fluorometil)fenil)etoxi) -3-(s) - (4-fluoro) fenil-4(3- (5-oxo-1h,4h-1,2,4-triazolo) metilmorfolino, processo para preparação da forma 1 do mesmo, composição farmacêutica, processo para antagonizar o efeito da substância p em seu sìtio receptor ou para o bloqueio dos receptores da neurocinina-1 em um mamìfero, processos para tratar ou prevenir uma condição selecionada, a êmese, um distúrbio do sistema nervoso central, a depressão, a ansiedade, e esquizofrenia em um mamìfero, e produto
TH77074A (th) องค์ประกอบทางเภสัชกรรมของสารต้านตัวรับแทคคีไคนิน
MX9702532A (es) Composiciones farmaceuticas para el tratamiento de la rinitis.
TH17690B (th) รูปแบบโพลีมอร์ฟิกของยาต้านฤทธิ์ตัวรับของแทกกีคินิน
TH47996A (th) รูปแบบโพลีมอร์ฟิกของยาต้านฤทธิ์ตัวรับของแทกกีคินิน

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

Owner name: SCHERING CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20140701

Year of fee payment: 17

PBON Lapse due to non-payment of renewal fee

Effective date: 20150701